{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-23-000005","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2023-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.344720+00:00","generated_at":"2026-06-19T12:40:47.204160+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biogen Q4 2022 rev $2.54B; GAAP EPS $3.79; guides FY2023 Non-GAAP EPS $15-$16","bullets":["Q4 revenue $2,544M, GAAP EPS $3.79, Non-GAAP EPS $4.05.","FY2022 revenue $10,173M (-7% YoY); GAAP EPS $20.87; Non-GAAP EPS $17.67 (-8% YoY).","FY2023 guidance: mid-single digit revenue decline; Non-GAAP EPS $15.00-$16.00.","LEQEMBI (lecanemab) granted FDA accelerated approval; traditional filing submitted in US, EU, Japan, China.","Zuranolone NDA for MDD/PPD accepted with Priority Review; PDUFA date August 5, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-23-000005","json":"https://secwatch.observer/filing/0000875045-23-000005.json","markdown":"https://secwatch.observer/filing/0000875045-23-000005.md","text":"https://secwatch.observer/filing/0000875045-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/biib-20230215.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:40:47.204160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0cc72d55fcda341ea76226d7006e036b5078e49a","claim":"BIOGEN INC. reported the fourth quarter and year ended December 31, 2022 results: revenue $2,544 million, net income GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05, EPS GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05.","evidence_excerpt":"growth drivers; Company reports full year 2022 results and provides full year 2023 guidance Full year 2022 revenue and Non-GAAP EPS exceed guidance • Fourth quarter revenue $2,544 million; GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05 • Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67 Positioned to lead in Alzheimer’s","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$2,544 million"},{"label":"Net income","value":"GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05"},{"label":"EPS","value":"GAAP diluted EPS $3.79; Non-GAAP diluted EPS $4.05"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d37bcaaa72c81ace1046d296652313ac4449f354","claim":"BIOGEN INC. reported full year 2023 results: EPS $15.00 to $16.00. Guidance initiated.","evidence_excerpt":"Full Year 2023 Financial Guidance • Expect mid-single digit revenue decline versus 2022 and Non-GAAP EPS of $15.00 to $16.00","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"EPS","value":"$15.00 to $16.00"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"dc87f86d834142326cdeaf5f31cb074969b0b7b0","claim":"BIOGEN INC. reported full year 2022 results: revenue $10,173 million, net income GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67, EPS GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67.","evidence_excerpt":"Full year revenue $10,173 million; GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875045/000087504523000005/0000875045-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$10,173 million"},{"label":"Net income","value":"GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67"},{"label":"EPS","value":"GAAP diluted EPS $20.87; Non-GAAP diluted EPS $17.67"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}